P01.034 Prospective evaluation of alternative therapies in glioma patients in France
Émilie Le Rhun(University of Zurich), Nicolas Simon(Université de Lille), Matthieu Boone(Ghent University), Michael Weller(University Hospital of Zurich), Luc Taillandier(Centre Hospitalier Universitaire de Caen Normandie), Véronique Lorgis(UniCancer Group), Patrick Devos(Hôpital Jeanne de Flandre), Nicolas Reyns(Centre National de la Recherche Scientifique), Elsa Curtit(Inserm), Christine Lebrun‐Frénay(Université Côte d'Azur), V. Bourg(Centre Hospitalier Universitaire de Nice), L. Gras(Pôle Léonard de Vinci), Guido Ahle(Hopitaux Civils de Colmar), Claudio Vásquez Ramirez, Amélie Darlix(Institut de Recherche en Cancérologie de Montpellier)
Cited by 0
Related Papers
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
|The Lancet Oncology|2017|1.1k
European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas
|The Lancet Oncology|2017|1.1k
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994